<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>FDA批准Biogen的Alzheimer的药物，近二十年的第一次治疗 FDA approves Biogen’s Alzheimer’s drug, the first therapy in nearly two decades</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">FDA approves Biogen’s Alzheimer’s drug, the first therapy in nearly two decades<br/>FDA批准Biogen的Alzheimer的药物，近二十年的第一次治疗 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-06-08 00:22:39</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/6/a3e52ed736db7a2d0e82f6fefe2e736c.jpeg"><img src="http://img2.diglog.com/img/2021/6/a3e52ed736db7a2d0e82f6fefe2e736c.jpeg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>The Food and Drug Administration on Monday approved  Biogen&#39;s Alzheimer&#39;s disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer&#39;s and the first new medicine for the disease in nearly two decades.</p><p>在周一批准的生物原生物原＆＃39; S疾病药物＆＃39; S疾病药物的食品和药物疾病＆＃39; S疾病药物阿杜曼宫，使其成为美国监管机构的第一批药物，以缓慢与阿尔茨海默氏症＆＃39; s和第一种新药的人们缓慢认知下降近二十年的疾病。</p><p> The FDA&#39;s decision was highly anticipated. The drug, which is marketed under the name Aduhelm, is also expected to generate billions of dollars in revenue for the company and  offers new hope to friends and families of patients living with the disease. Biogen&#39;s stock was halted for the announcement.</p><p> FDA＆＃39;决定高度预期。该贩售在Aduhelm的名称下，也有望为本公司产生数十亿美元，为患有疾病的患者和患者家族提供新的希望。生物原性＆＃39;股票被停止宣布。</p><p>  &#34;We are well-aware of the attention surrounding this approval,&#34; Dr. Patrizia Cavazzoni, director of the FDA&#39;s Center for Drug Evaluation and Research, said in a press release. &#34;We understand that Aduhelm has garnered the attention of the press, the Alzheimer&#39;s patient community, our elected officials, and other interested stakeholders.&#34;</p><p>  ＆＃34;我们很清楚围绕此批准的关注，＆＃34; FDA＆＃39; SCAL评估和研究中心主任Patrizia Cavazzoni博士在新闻稿中表示。 &#34;We understand that Aduhelm has garnered the attention of the press, the Alzheimer&#39;s patient community, our elected officials, and other interested stakeholders.&#34;</p><p> &#34;With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review,&#34; Cavazzoni added.</p><p> ＆＃34;对于平衡的严重，危及生命的疾病的治疗，有意义的是，这么多人都在遵循本综述的结果，而＃34; Cavazzoni补充道。</p><p> The FDA said it will continue to monitor the drug as it reaches the U.S. market. The agency granted approval on the condition that Biogen conduct another clinical trial.</p><p> FDA表示，它将继续监测药物，因为它将成为您的市场。该机构批准了生物生成另一次临床试验的条件。</p><p> Alzheimer&#39;s disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. More than 6 million Americans are living with it, according to  estimates by the Alzheimer&#39;s Association. By 2050, that number is projected to rise to nearly 13 million, according to the group.</p><p> Alzheimer＆＃39; S病是一种慢性的神经变性疾病，慢慢地破坏记忆和思维技能。根据Alzheimer＆＃39; S协会的估计，根据Alzheimer的估计，超过600万美国人居住。根据本集团的说法，到2050年，该数字预计将上升到近1300万。</p><p> &#34;It is a new day,&#34; Harry Johns, CEO of the Alzheimer&#39;s Association, said in a statement. &#34;This approval allows people living with Alzheimer&#39;s more time to live better. For families it means being able to hold on to their loved ones longer. It is about reinvigorating scientists and companies in the fight against this scourge of a disease. It is about hope.&#34;</p><p> ＆＃34;这是新的一天，＆＃34;阿尔茨海默鹞首席执行官哈里约翰在一份声明中表示。 ＆＃34;此批准允许与阿尔茨海默氏症生活的人＆＃39;更多的时间更好地生活。对于家庭来说，这意味着能够坚持自己的亲人。它是关于将科学家和公司加入抗击这种疾病的祸害。这是希望。＆＃34; </p><p>  There were previously no drugs cleared by the FDA that can slow the mental decline from Alzheimer&#39;s, which is the sixth-leading cause of death in the United States. The agency has approved Alzheimer&#39;s drugs aimed at helping symptoms, not actually slowing the disease itself.</p><p>FDA以前没有清除药物，可以减缓阿尔茨海默氏症的精神衰退，这是美国的第六名派对死亡原因。该机构已批准Alzheimer＆＃39; S旨在帮助症状的药物，实际上并没有减缓疾病本身。</p><p> Federal regulators have faced intense pressure from friends and family members of Alzheimer&#39;s patients asking to fast-track aducanumab, but the road to regulatory approval has been a controversial one since it showed promise in 2016.</p><p> 联邦监管机构面临着阿尔茨海默氏症的朋友和家人的强烈压力＆＃39;患者要求快速轨道的奥杜纳布，但监管批准的道路是一个有争议的人，因为它在2016年表明承诺。</p><p> In March 2019, Biogen pulled work on the drug after an analysis from an independent group revealed it was unlikely to work. The company then shocked investors several months later by announcing it would seek regulatory approval for the drug after all.</p><p> 2019年3月，生物原在一个独立小组分析后揭示了揭示了不太可能的药物。然后，该公司几个月后令人震惊的投资者通过宣布它会毕竟会寻求对药物的监管批准。</p><p> Shares of Biogen soared in November  after it won backing from FDA staff, who said the company showed highly &#34;persuasive&#34; evidence aducanumab was effective and that it had &#34;an acceptable safety profile that would support use in individuals with Alzheimer&#39;s disease.&#34;</p><p> 11月份的生物原生物体股票在FDA工作人员赢得后，他表示，该公司表现出高度＆＃34;有说服力的＆＃34;证据Aducanumab是有效的，它有＆＃34;一个可接受的安全型材，可以支持与阿尔茨海默氏症的个人使用。＆＃34;</p><p> But two days later, a panel of outside experts that advises the  U.S. agency unexpectedly declined to endorse the experimental drug, citing unconvincing data. It also criticized agency staff for what it called an overly positive review.</p><p> 但两天后，一个外部专家的小组，建议美国机构意外拒绝支持实验药物，引起令人信服的数据。它还批评了代理工作人员所谓的过度积极审查。</p><p> When Biogen sought approval for the drug in late 2019, its scientists said a new analysis of a larger dataset showed aducanumab &#34;reduced clinical decline in patients with early Alzheimer&#39;s disease.&#34;</p><p> 当Biogen在2019年底寻求批准该药物时，其科学家们表示，对较大的数据集进行了新的分析，显示了Aducanumab＆＃34;患有早期阿尔茨海默氏症患者的临床下降＆＃34;</p><p> Alzheimer&#39;s experts and Wall Street analysts were immediately skeptical, with some wondering whether the clinical trial data was enough to prove the drug works and whether approval could make it harder for other companies to enroll patients in their own drug trials.</p><p> Alzheimer＆＃39; S专家和华尔街分析师立即持怀疑态度，有些人想知道临床试验数据是否足以证明药物工作，以及批准是否可以使其他公司在自己的药物试验中注册患者。 </p><p> Some doctors  have said they won&#39;t prescribe aducanumab if it does reach the market, because of the mixed data package supporting the company&#39;s application.</p><p>一些医生说他们赢得了＆＃39;如果它确实达到了市场，那么由于支持公司的混合数据包和应用程序。</p><p> Supporters, including advocacy groups and family members of those living with the disease desperate for a new treatment, have acknowledged the data isn&#39;t perfect. However, they contend it could help some patients with Alzheimer&#39;s, a progressive and debilitating disease.</p><p> 支持者，包括倡导团体和家庭成员与疾病的人渴望进行新的待遇，已承认数据ISN＆＃39; t完美。然而，他们争辩它可以帮助一些患有阿尔茨海默疱疹的患者，逐步和衰弱的疾病。</p><p>  Biogen&#39;s drug targets a &#34;sticky&#34; compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease. The company has previously estimated about 1.5 million people with early Alzheimer&#39;s in the U.S. could be candidates for the drug, according to Reuters.</p><p>  生物原性＆＃39; S药物目标A＆＃34;粘滞＆＃34;脑中的化合物称为β-淀粉样蛋白，科学家期望在毁灭性疾病中发挥作用。根据路透社的说法，该公司之前估计了150万人患有早期的阿尔茨海默＆＆＃39;在美国候选人。</p><p> The approval is &#34;interesting as the FDA is essentially confirming here that the beta-amyloid hypothesis has been validated,&#34; Salim Syed, a senior biotech analyst at Mizuho Securities, said Monday, adding the decision will have major implications for future clinical trials. Some experts aren&#39;t convinced targeting the compound will slow cognitive decline.</p><p> 批准是＆＃34;有趣的是，因为FDA基本上证实了β-淀粉样蛋白假设已被验证，＆＃34; Mizuho Securities的一名生物技术分析师Salim Syed表示，周一表示，补充该决定将对未来的临床试验产生重大影响。一些专家Aren＆＃39;令人信服的靶向化合​​物会缓慢认知衰退。</p><p> The FDA decision is expected to reverberate throughout the biopharma sector, RBC Capital Markets analyst Brian Abrahams said in a note to clients on June 1.</p><p> RBC Capital Markets Analyst Brian Abrahams预计FDA决定预计将在整个生物野蛮行业中回荡，这是6月1日至客户的一份客户。</p><p> The U.S. agency said Monday it determined there was &#34;substantial evidence&#34; the drug helps patients. &#34;As a result of FDA&#39;s approval of Aduhelm, patients with Alzheimer&#39;s disease have an important and critical new treatment to help combat this disease,&#34; it said.</p><p> 美国机构周一表示，它确定了有＆＃34;实质证据＆＃34;该药有助于患者。 ＆＃34;由于FDA＆＃39; Aduhelm的批准，阿尔茨海默氏症患者＆＃39; S病有一个重要且批判的新待遇，以帮助打击这种疾病，＆＃34;它说。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html">https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/批准/">#批准</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/approves/">#approves</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/药物/">#药物</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>